Sector News

Integra LifeSciences to spin off spine unit

November 5, 2014
Life sciences
(Reuters) – Surgical devices and orthopedic care company Integra LifeSciences Holdings Corp said it would spin off its spine unit in an attempt to streamline its operations.
 
The company will continue to produce specialty surgical products and orthopedics and tissue therapies, while the new company will be called SeaSpine.
 
The company, which expects to take a one-time charge on the spin-off, revised its full-year profit forecast to 81-99 cents a share, down from its earlier forecast of $1.06 to $1.24 per share.
 
Piper Jaffray & Co. served as the company’s financial advisor, while Latham & Watkins LLP was the legal counsel in connection with the proposed spin-off transaction.
 
(Reporting by Vidya L Nathan in Bangalore; Editing by Joyjeet Das)

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”